MedImmune Inc. and the New York Blood Center announcedFriday that they have filed a product license application (PLA)with the FDA for MelGAM, an intravenous immune globulinproduct, for treating primary humoral immunodeficiencies andidiopathic thrombocytopenic purpura (ITP).

MelGAM, a liquid intravenous immune globulin treated with apatented solvent/detergent process to inactivate viruses inplasma proteins, was developed by Melville Biologics, a divisionof the New York Blood Center. In September MedImmune ofGaithersburg, Md., signed a letter of intent to purchase MelvilleBiologics, including rights to MelGAM. MedImmune(NASDAQ:MEDI) and the New York Blood Center expect tocomplete the $40 million-transaction this year. -- Jennifer VanBrunt

(c) 1997 American Health Consultants. All rights reserved.